Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
Status:
RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)